- Samsung Biologics’ 2Q Operating Profit: Achieved 475.60 billion won, marking a 9.5% increase from the previous year.
- Exceeded Estimates: The operating profit surpassed market expectations of 452.78 billion won.
- Net Income Growth: Recorded a net income of 324.39 billion won, representing a 2% year-over-year increase.
- Below Net Income Estimates: The net income fell short of the estimated 369.4 billion won.
- Sales Performance: Reported sales grew by 11% year-over-year to 1.29 trillion won.
- Sales Estimates: Sales did not meet the anticipated 1.39 trillion won.
- Analyst Ratings: The company is currently rated with 31 buy, 1 hold, and 0 sell recommendations.
Samsung Biologics on Smartkarma
Analysts on Smartkarma have been actively covering Samsung Biologics, providing valuable insights for investors. Brian Freitas discussed the potential changes in the FnGuide Top 10 Index, highlighting the historical performance of trading strategies. Sanghyun Park clarified market uncertainties surrounding the Samsung Biologics spin-off, emphasizing the impact on shareholder value and potential trading opportunities. Douglas Kim focused on Samsung Biologics’ creation of a holding company to split its CDMO and biosimilar businesses, anticipating varied reactions to this strategic move.
Additionally, Sanghyun Park addressed the confusion regarding Samsung C&T’s forced holding company conversion, shedding light on the key trade angle in the Biologics split play. Another report by Sanghyun Park highlighted Korea’s FSC rolling out the legal framework for fractional share trading, signaling potential flow changes and market liquidity enhancements. These diverse perspectives offer investors a comprehensive view of the developments surrounding Samsung Biologics and strategic insights for investment decisions.
A look at Samsung Biologics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Samsung Biologics shows a promising long-term outlook. With a high Growth score of 5, the company is primed for strong expansion and development opportunities in the future. The Resilience score of 4 indicates a company well-equipped to withstand market fluctuations and challenges, providing a sense of stability for potential investors.
Although the Dividend score is lower at 1, the overall positive scores in Value, Growth, Resilience, and Momentum position Samsung Biologics favorably for potential long-term success in the biopharmaceutical industry. With its focus on manufacturing bio-healthcare products and distributing biopharmaceuticals, Samsung Biologics is poised to capitalize on the growing demand for innovative healthcare solutions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
